News | Radiology Business | June 27, 2019

Blue Earth Diagnostics to be Acquired by Bracco Imaging

Blue Earth Diagnostics to become a subsidiary of Bracco Imaging; retains name and management team

Blue Earth Diagnostics, a molecular imaging diagnostics company, announced that a definitive agreement has been signed for Bracco Imaging S.p.A. to acquire all outstanding shares of privately-held Blue Earth Diagnostics from leading healthcare company Syncona for $450 million plus closing adjustment estimated at $25 million. Upon closing of the transaction, Blue Earth Diagnostics will be a subsidiary of Bracco Imaging, led by its current leadership team and will retain the well-established Blue Earth Diagnostics name. Bracco Imaging is a leader in the diagnostic imaging business with an integrated product offering from a diverse roster of subsidiary companies.

“The acquisition of Blue Earth Diagnostics by Bracco Imaging is a validation of the quality of our people, our pipeline of novel diagnostic agents such as rhPSMA and the proven success of Axumin for imaging in prostate cancer and potentially other future indications,” said Jonathan Allis, D.Phil., chief executive officer, Blue Earth Diagnostics. “We believe this acquisition is excellent for Blue Earth as Bracco Imaging’s global footprint and clinical research and marketing support will enable us to expand the reach of our high-value platform of innovative radiopharmaceuticals to inform clinical management and guide care for even more people with cancer around the world.”

Blue Earth Diagnostics’ first commercialized product, Axumin (fluciclovine F 18) injection is a novel molecular imaging agent approved in the United States and the European Union for use in PET imaging for men with suspected recurrent prostate cancer. Axumin is widely available and used across the United States, with more than 50,000 doses administered to date. 18F-Fluciclovine has a broad range of other potential applications in cancer imaging and Blue Earth Diagnostics is investigating the molecule for utility in other cancers, including in neuro-oncology.

In April 2018, Blue Earth Diagnostics expanded its prostate cancer portfolio through the acquisition of exclusive, worldwide rights to a broad family of Prostate Specific Membrane Antigen (PSMA)-targeted radiohybrid (“rh”) agents for cancer. rhPSMA is a clinical-stage, investigational class of theranostic compounds, with potential applications in both the imaging and treatment of prostate cancer.

“Blue Earth Diagnostics’ innovative products and pipeline will significantly enhance Bracco Imaging’s portfolio in precision medicine and personalized diagnostics, while expanding our range of nuclear oncology imaging solutions in the Urology segment and other specialties,” said Fulvio Renoldi Bracco, Chief Executive Officer, Bracco Imaging. “We are thrilled to welcome to Bracco this world class team with exceptional product development and commercialization expertise.”

“We are so proud of our exceptional, patient-focused team for building a successful radiopharmaceuticals business in only five years. This acquisition provides us the tremendous opportunity to grow and expand Axumin, and our innovative pipeline, geographically and into other therapeutic targets,” added Allis. “We also wish to acknowledge Syncona for its role in the foundation of the company, and its operational and financial acumen as we have built the business.”

For more information: www.braccoimaging.com

Related Content

Nurse Practitioners, Physician Assistants Rarely Interpret Diagnostic Imaging Studies
News | Radiology Business | September 18, 2019
September 18, 2019 — Although Medicare claims data confirm the...
Scranton Gillette Communications Names Imaging Technology News Group Publisher and Integrated Media Consultant

Diane Vojcanin (left) was named vice president, group publisher, healthcare group, overseeing Imaging Technology News (ITN) and Diagnostic and Interventional Cardiology (DAIC). Andreja Slapsys (right) was named a healthcare group integrated media consultant.

News | Radiology Business | September 06, 2019
Business-to-business communications leader Scranton Gillette Communications has named Diane Vojcanin as vice president...
AJR Publishes Gender Affirmation Surgery Primer for Radiologists. transgender radiology images,

Scout image from contrast-enhanced CT shows erectile implant; stainless steel and silicone anchors (arrow) transfixed to pubic bone are asymmetric.

News | Orthopedic Imaging | September 05, 2019
September 5, 2019 — An ahead-of-print article published in the December issue of the American Journal of Roentgen
Medical Imaging Rates Continue to Rise Despite Push to Reduce Their Use
News | Radiology Imaging | September 03, 2019
Despite a broad campaign among physician groups to reduce the amount of medical imaging, use rates of various scans...
Beginning with the 2019 meeting, the American Society for Radiation Oncology (ASTRO) will begin transforming its annual meeting in several key ways

Expect changes at ASTRO 2019 and at ASTRO annual meetings to come over the next two years. Photo courtesy of ASTRO

Feature | ASTRO | August 30, 2019 | By Greg Freiherr
Beginning with the...
RSNA Announces New Global Learning Centers Program
News | Radiology Business | August 26, 2019
The Radiological Society of North America (RSNA) is launching a new RSNA Global Learning Centers (GLC) program...
Videos | Radiology Business | August 02, 2019
Association for Medical Imaging Management (AHRA) President ...
Feature | Information Technology | July 31, 2019 | By Greg Freiherr
Innovation is trending toward improved efficiency — but not at the expense of patient safety, according to...
Demand for ultrasound scans at U.S. outpatient centers could grow by double digits over the next five years, according to a speaker at AHRA 2019. A variety of factors, however, could cause projections for this and other modalities to change. Graphic courtesy of Pixabay

Demand for ultrasound scans at U.S. outpatient centers could grow by double digits over the next five years, according to a speaker at AHRA 2019. A variety of factors, however, could cause projections for this and other modalities to change. Graphic courtesy of Pixabay

Feature | Radiology Imaging | July 29, 2019 | By Greg Freiherr
The coming years may be good for the medical imaging community in the United States. But they will not be easy.